Drug Profile
A-dmDT390-anti-CD3 immunotoxin
Alternative Names: A-dmDT390-bisFv; A-dmDT390-bisFv(UCHT1); Anti-CD3 antibody-diphtheria toxin conjugate; Anti-CD3 bivalent antibody-diphtheria toxin conjugate; LAX-699; Recombinant anti-CDR-bi-single-chain-Fv-diptheria toxin fusion protein; Resimmune; UCHT-1-AngimmuneLatest Information Update: 20 Dec 2016
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA)
- Developer Angimmune; University of Louisville
- Class Drug conjugates; Immunotoxins; Peptides
- Mechanism of Action Peptide elongation factor 2 inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Cutaneous T-cell lymphoma; Malignant melanoma
Most Recent Events
- 20 Dec 2016 Angimmune plans a phase I/II trial for Melanoma (late-stage disease; Adjunctive therapy) in USA (NCT02990416)
- 30 Nov 2016 Angimmune completes a phase II trial in Cutaneous T-cell lymphoma in USA (NCT00611208)
- 22 Nov 2016 Angimmune terminates a phase-I/II clinical trial in Malignant melanoma (Combination therapy, Late-stage disease, Metastatic disease) in USA (Parenteral) (NCT01888081)